Original Article

You have full text access to this OnlineOpen article

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

  1. Alessandra Ferrajoli M.D.1,†,*,
  2. Susan M. O'Brien M.D.1,
  3. Jorge E. Cortes M.D.1,
  4. Francis J. Giles M.D.1,
  5. Deborah A. Thomas M.D.1,
  6. Stefan Faderl M.D.1,
  7. Razelle Kurzrock M.D.2,
  8. Susan Lerner M.S.1,
  9. Dimitrios P. Kontoyiannis M.D.3,
  10. Michael J. Keating M.B., B.S.1

Article first published online: 26 JUN 2003

DOI: 10.1002/cncr.11551

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 773–778, 15 August 2003

Additional Information

How to Cite

Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A., Faderl, S., Kurzrock, R., Lerner, S., Kontoyiannis, D. P. and Keating, M. J. (2003), Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 98: 773–778. doi: 10.1002/cncr.11551

Author Information

  1. 1

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Bioimmunotherapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Infectious Diseases, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 794-4297

*Department of Leukemia/Unit 428, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 26 JUN 2003
  3. Manuscript Accepted: 27 APR 2003
  4. Manuscript Revised: 10 APR 2003
  5. Manuscript Received: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (82K)

Keywords:

  • alemtuzumab;
  • lymphoproliferative disorders;
  • chronic lymphocytic leukemia (CLL);
  • prolymphocytic leukemia (PLL);
  • toxicity;
  • infections

Abstract

BACKGROUND

Pilot studies showed that alemtuzumab is active in lymphoproliferative disorders. The authors conducted a Phase II trial to evaluate the efficacy and safety of alemtuzumab in advanced or refractory chronic lymphoproliferative disorders.

METHODS

Seventy-eight patients were enrolled. The most common diagnoses were chronic lymphocytic leukemia (n = 42 patients) and T-cell prolymphocytic leukemia (n = 18 patients). Before entering the study, the patients had received multiple therapies (median, three therapies) and the median time from diagnosis was 7 years. Alemtuzumab was given intravenously at doses of 3 mg, 10 mg, and 30 mg on 3 consecutive days, after which 30 mg was administered 3 times a week. Patients were treated for 4–12 weeks depending on disease response. All patients received prophylactic trimethoprim/sulfamethoxazole and valacyclovir.

RESULTS

The overall response rate was 35%, the complete response (CR) rate was 13%, and the partial response (PR) rate was 22%. The median duration of response was 18 months for patients achieving a CR and 7 months for patients achieving a PR. The median duration of survival was 25 months for patients who had a response and 12 months for the entire population. Normalization of the lymphocyte count was observed in 84% of patients and resolution of bone marrow involvement was observed in 49% of patients. The most common infusion-related adverse events were fever, rigors, skin rash, nausea, and dyspnea. These were most common during the first week of therapy. Hematologic toxicity was comprised of long-lasting lymphocytopenia and transient neutropenia and thrombocytopenia. Thirty-six patients (46%) experienced at least one episode of fever or infection.

CONCLUSIONS

Alemtuzumab has a high response rate in patients with chronic lymphoproliferative disorders. Cancer 2003;98:773–8. © 2003 American Cancer Society.

DOI 10.1002/cncr.11551

View Full Article (HTML) Get PDF (82K)